See more : Humanigen, Inc. (HGENQ) Income Statement Analysis – Financial Results
Complete financial analysis of Soleno Therapeutics, Inc. (SLNO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Soleno Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Golf & Co Group Ltd (GOLF.TA) Income Statement Analysis – Financial Results
- CTI BioPharma Corp. (CTIC) Income Statement Analysis – Financial Results
- Masterbeat Corporation (MSTO) Income Statement Analysis – Financial Results
- Dune Acquisition Corporation (DUNEU) Income Statement Analysis – Financial Results
- Macromill, Inc. (MCCLF) Income Statement Analysis – Financial Results
Soleno Therapeutics, Inc. (SLNO)
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.55B | 1.45M | 387.56K | 0.00 | 3.00M | 0.00 |
| Cost of Revenue | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 1.51M | 352.68K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.96M | -2.21M | -2.21M | -2.19M | -2.30M | -1.92M | -1.55B | -58.52K | 34.87K | 0.00 | 3.00M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.10% | -4.03% | 9.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 25.19M | 15.27M | 21.45M | 23.19M | 16.27M | 7.18M | 3.07M | 5.18M | 4.54M | 2.24M | 2.38M | 2.47M |
| General & Administrative | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.58M | 6.74M | 6.14M | 2.67M | 1.47M | 1.13M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.73K | 1.63M | 1.74M | 252.36K | 0.00 | 0.00 |
| SG&A | 13.48M | 9.84M | 10.81M | 8.76M | 6.93M | 6.56M | 6.61M | 8.37M | 7.88M | 2.92M | 1.47M | 1.13M |
| Other Expenses | 2.71M | 0.00 | 0.00 | 4.34M | 289.00K | 6.00K | -585.95K | -100.52K | -183.57K | -4.59M | -1.97K | -22.41K |
| Operating Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 13.55M | 12.19M | 5.16M | 3.85M | 3.60M |
| Cost & Expenses | 41.38M | 25.11M | 32.26M | 31.95M | 23.20M | 13.73M | 9.68M | 15.06M | 12.55M | 5.16M | 3.85M | 3.60M |
| Interest Income | 2.58M | 300.00K | 110.00K | 13.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 1.77K | 3.10K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.00K | 0.00 | 0.00 | 0.00 | 4.13M | 2.86M | 2.87M |
| Depreciation & Amortization | 1.96M | 2.21M | 2.21M | 2.19M | 2.30M | 1.92M | 1.61M | 19.70K | 108.23K | 28.52K | 42.11K | 43.79K |
| EBITDA | -37.03M | -21.86M | -28.70M | -30.00M | -28.48M | -9.92M | -8.07M | -6.72M | -15.80M | -5.13M | -804.86K | -3.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.30% | -1,043.96% | -3,943.82% | 0.00% | -26.83% | 0.00% |
| Operating Income | -41.38M | -24.40M | -31.53M | -36.29M | -23.49M | -14.30M | -12.17M | -13.61M | -12.16M | -5.16M | -846.78K | -3.60M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.78% | -938.12% | -3,137.55% | 0.00% | -28.23% | 0.00% |
| Total Other Income/Expenses | 2.40M | 330.00K | 618.00K | 11.65M | -7.29M | 2.46M | -1.27M | 1.59M | -3.75M | -8.08M | -2.86M | -2.88M |
| Income Before Tax | -38.99M | -24.07M | -30.91M | -24.64M | -30.77M | -11.84M | -13.72M | -12.04M | -15.91M | -13.87M | -3.71M | -6.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.88% | -830.14% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| Income Tax Expense | 0.00 | -3.75M | -1.35M | -9.26M | 5.14M | 2.52M | -1.65M | 21.70K | -183.57K | -455.08K | 2.86M | 2.84M |
| Net Income | -38.99M | -20.32M | -29.56M | -15.38M | -35.92M | -13.34M | -15.67M | -12.07M | -15.91M | -13.87M | -3.71M | -6.48M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.01% | -831.63% | -4,104.85% | 0.00% | -123.57% | 0.00% |
| EPS | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| EPS Diluted | -2.36 | -2.42 | -5.56 | -3.68 | -15.78 | -9.54 | -26.18 | -58.35 | -126.58 | -819.38 | -198.45 | -346.98 |
| Weighted Avg Shares Out | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
| Weighted Avg Shares Out (Dil) | 16.49M | 8.40M | 5.32M | 4.17M | 2.28M | 1.40M | 598.52K | 206.77K | 125.68K | 16.93K | 18.68K | 18.68K |
The 10 Most Shorted Stocks Include 3 Tesla Rivals, But Not TSLA
Would-be Tesla rivals VinFast and Fisker are among the most-shorted stocks. So are C3.ai and Upstart, which are big stock winners in 2023.
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
In a press release issued earlier this afternoon, the time zone of the FPWR Research Symposium presentation was labeled as Central Time. The correct time zone is Mountain Time.
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced an oral presentation at the Foundation for...
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
REDWOOD CITY, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing of the underwritten public offering of...
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of...
Why Shares of Soleno Therapeutics Dropped on Wednesday
Soleno announced on Tuesday top-line results for its lead therapy candidate. The company said it plans to submit a New Drug Application to the FDA regarding diazoxide choline controlled-release (DCCR) to treat Prader-Willi Syndrome.
Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of...
Soleno Stock Dives After Its Meteoric Rise
The biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal
Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.
Why Shares of Soleno Therapeutics Are Booming on Tuesday
Soleno specializes in treating rare metabolic disorders. The company's lead therapy, DCCR, fared well as a treatment for Prader-Willi syndrome.
Source: https://incomestatements.info
Category: Stock Reports